New experimental drug SIM0613 enters first human tests for advanced cancers

NCT ID NCT07618260

Recruiting now Disease control Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and early signs of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SIM0613 (an experimental drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not be safe or effective. Side effects are unknown, and it will take years to know if it truly helps patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID CANCER

Contacts and locations

Locations

Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.